AtriCure (NASDAQ:ATRC) Stock Price Target Raised at BTIG Research

Posted by Brian Himes on Oct 13th, 2026

AtriCure (NASDAQ:ATRC – Free Report) had its price target raised by BTIG Research from $55.00 to $63.00 in a research note issued to investors on Monday morning,Benzinga reports. The firm currently has a buy rating on the medical device company’s stock.

A number of other equities analysts also recently weighed in on ATRC. Citigroup reaffirmed a “market outperform” rating on shares of AtriCure in a research note on Tuesday, July 21st. Piper Sandler upped their target price on shares of AtriCure from $50.00 to $60.00 and gave the stock an “overweight” rating in a research report on Thursday, August 27th. Needham & Company LLC increased their price target on shares of AtriCure from $45.00 to $64.00 and gave the company a “buy” rating in a research note on Wednesday, September 2nd. Raymond James Financial set a $52.00 price target on shares of AtriCure in a research note on Tuesday, July 21st. Finally, Zacks Research lowered shares of AtriCure from a “strong-buy” rating to a “hold” rating in a report on Monday, August 24th. Seven analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $54.10.

View Our Latest Report on ATRC

AtriCure Stock Performance

Shares of NASDAQ:ATRC opened at $57.28 on Monday. AtriCure has a twelve month low of $25.36 and a twelve month high of $61.70. The firm has a market cap of $2.91 billion, a PE ratio of 272.77 and a beta of 1.24. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22. The business has a fifty day moving average of $51.33 and a 200-day moving average of $37.50.

AtriCure (NASDAQ:ATRC – Get Free Report) last issued its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The business had revenue of $153.60 million for the quarter, compared to the consensus estimate of $151.80 million. During the same quarter in the prior year, the company earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, equities research analysts predict that AtriCure will post 0.29 EPS for the current fiscal year.

Insider Buying and Selling at AtriCure

In other news, insider Karl Dahlquist sold 9,370 shares of the company’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $48.89, for a total transaction of $458,099.30. Following the transaction, the insider owned 87,319 shares of the company’s stock, valued at $4,269,025.91. This represents a 9.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Sven Wehrwein sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $37.84, for a total value of $946,000.00. Following the completion of the transaction, the director owned 40,518 shares in the company, valued at approximately $1,533,201.12. This represents a 38.16% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 74,868 shares of company stock valued at $3,317,897 over the last ninety days. Company insiders own 4.00% of the company’s stock.

Institutional Investors Weigh In On AtriCure

Institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. acquired a new position in AtriCure in the second quarter valued at approximately $125,198,000. Wellington Management Group LLP grew its holdings in AtriCure by 3.3% during the 2nd quarter. Wellington Management Group LLP now owns 3,495,603 shares of the medical device company’s stock worth $97,807,000 after acquiring an additional 113,048 shares during the period. Dimensional Fund Advisors LP grew its holdings in AtriCure by 8.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 997,759 shares of the medical device company’s stock worth $28,466,000 after acquiring an additional 75,862 shares during the period. Bank of America Corp DE acquired a new stake in AtriCure during the 2nd quarter worth $24,465,000. Finally, Grandeur Peak Global Advisors LLC acquired a new stake in AtriCure during the 2nd quarter worth $16,435,000. 99.11% of the stock is owned by institutional investors.

About AtriCure

(Get Free Report)

AtriCure, Inc is a medical device company focused on developing and commercializing technologies for the treatment of atrial fibrillation (AF) and related cardiac conditions. Its products are used primarily in cardiac surgery and electrophysiology procedures to create surgical lesions that interrupt abnormal electrical signals in the heart.

The company’s portfolio includes the AtriCure Isolator Synergy ablation system, cryoablation products sold under the cryoICE brand, and the AtriClip system for the exclusion of the left atrial appendage, a potential source of blood clots in patients with AF.